Intravenous foscarnet for the treatment of severe cytomegalovirus infection in allograft recipients.
about
Synergistic effect of ganciclovir and foscarnet on cytomegalovirus replication in vitroCombinations of 3'-azido-3'-deoxythymidine (zidovudine) and phosphonoformate (foscarnet) against human immunodeficiency virus type 1 and cytomegalovirus replication in vitroTreatment of CMV retinitis in an AIDS patientSynergistic inhibition of human T-cell lymphotropic virus type III replication in vitro by phosphonoformate and recombinant alpha-A interferonChemotherapeuticsNew strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipientsCytomegalovirus infection and disease after liver transplantation. An overview.Foscarnet treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome.Pharmacokinetics of intermittently administered intravenous foscarnet in the treatment of acquired immunodeficiency syndrome patients with serious cytomegalovirus retinitis.Infections in solid-organ transplant recipientsAntiviral therapy: current concepts and practicesBone marrow transplantation and the lung.Herpesvirus and enteric viral infections in bone marrow transplantation: clinical presentations, pathogenesis, and therapeutic strategies.Cytomegalovirus infection after organ transplantation: an update with special emphasis on renal transplantation.Fiberoptic bronchoscopy for diagnosis of opportunistic pulmonary infections after bone marrow transplantation.Pharmacokinetics of foscarnet and distribution to cerebrospinal fluid after intravenous infusion in patients with human immunodeficiency virus infection.Ganciclovir-resistant cytomegalovirus clinical isolates: mode of resistance to ganciclovir.Cytomegalovirus infections in renal transplant patients.Comparative activity of selected antiviral compounds against clinical isolates of human cytomegalovirus.Activity of different antiviral drug combinations against human cytomegalovirus replication in vitro.
P2860
Q28330357-8BE0D5D1-5779-492A-B469-B9D473C82EC0Q28342758-4B593CE1-8816-4279-BA3C-541BD2A4600AQ28359800-1E2B0DBA-F97D-46A0-865F-0AFEA54F74ECQ28360426-F943EF8C-8EB2-47F1-8E97-BBE309AABBDEQ30047670-3F55500E-01F1-4B4B-AE85-A8932D4BA434Q33812425-128EA326-4BDC-492D-9EC8-7B909700E46CQ35227146-1DA5F2DA-F833-4A83-9485-8241A911770BQ35333512-914E4B1A-2D7F-48A7-A491-D10DCE40C680Q35333643-B4BC661C-5AA4-451F-874C-046803489D39Q35376486-0A6D97EA-47B8-46FE-9C38-E91A2375142EQ36070394-E4CEA487-7BDD-4A9A-99FD-47FDE9F44753Q36156348-9E1BAB03-257E-46E5-B28B-666F4D419B8CQ37901418-591EBBEC-3C7C-4995-9F21-91B36EA7E2DDQ38296461-B4BC092F-A624-4F0F-95E4-A452507C6D38Q38727381-07F98DC2-4DF6-43DB-97FC-245E1BD8C07DQ39833019-107F2799-CCB3-4CDB-A86A-07F58BD3DB44Q40087885-26F13849-98AF-423F-A42F-34B7D985906BQ40708345-58E7EB71-6398-4C1C-947E-FF137F7E0FAEQ41655592-810D7C61-376E-4ECE-B151-680464FE0CA3Q54257052-72529072-4109-4912-B187-60E22210261C
P2860
Intravenous foscarnet for the treatment of severe cytomegalovirus infection in allograft recipients.
description
1985 nî lūn-bûn
@nan
1985年の論文
@ja
1985年学术文章
@wuu
1985年学术文章
@zh
1985年学术文章
@zh-cn
1985年学术文章
@zh-hans
1985年学术文章
@zh-my
1985年学术文章
@zh-sg
1985年學術文章
@yue
1985年學術文章
@zh-hant
name
Intravenous foscarnet for the ...... ction in allograft recipients.
@en
Intravenous foscarnet for the ...... ction in allograft recipients.
@nl
type
label
Intravenous foscarnet for the ...... ction in allograft recipients.
@en
Intravenous foscarnet for the ...... ction in allograft recipients.
@nl
prefLabel
Intravenous foscarnet for the ...... ction in allograft recipients.
@en
Intravenous foscarnet for the ...... ction in allograft recipients.
@nl
P2093
P2860
P1476
Intravenous foscarnet for the ...... ction in allograft recipients.
@en
P2093
Klintmalm G
Lernestedt JO
Lundgren G
Lönnqvist B
P2860
P304
P356
10.3109/INF.1985.17.ISSUE-2.06
P577
1985-01-01T00:00:00Z